CJC-1295 + Ipamorelin Blend
Common secretagogue blend reconstituted as a protocol: GHRH (CJC-1295 no DAC) + GHRP (ipamorelin) dosed together 3×/week for synergistic GH release.
Concentration over time
| Date | CJC-1295 without DAC (Modified GRF 1-29) | Ipamorelin |
|---|---|---|
| W1 | 0.00 | 0.00 |
| W1 | 0.00 | 0.01 |
| W2 | 0.00 | 0.10 |
| W3 | 0.00 | 0.00 |
| W3 | 0.00 | 0.01 |
| W4 | 0.00 | 0.10 |
| W5 | 0.00 | 0.00 |
| W5 | 0.00 | 0.01 |
| W6 | 0.00 | 0.10 |
| W7 | 0.00 | 0.00 |
| W7 | 0.00 | 0.01 |
| W8 | 0.00 | 0.10 |
| W9 | 0.00 | 0.00 |
Protocol summary
CJC-1295 + Ipamorelin Blend · 8 weeks starting Jul 20, 26
- CJC-1295 without DAC (Modified GRF 1-29) — 300 mcg Every day, weeks 0–8
- Ipamorelin — 300 mcg Every day, weeks 0–8
Protocol overview
- Category
- peptide stack
- Duration
- 8 weeks
- Compounds
- 2
- Tags
- secretagogue, gh, cjc-1295, ipamorelin, blend, peptide
Compounds in this protocol
- CJC-1295 (no DAC) — 0.3 mg, every-day
- Ipamorelin — 0.3 mg, every-day
How to read this protocol
The chart above shows the modeled blood concentration of each compound over the 8-week duration. Each compound accumulates toward steady state (roughly 5 half-lives). The peak-to-trough ratio within each dose interval depends on the injection frequency relative to the half-life.
Use the [peak-trough estimator](/tools/peak-trough) to see predicted levels at any point, or the [clearance calculator](/tools/clearance) to estimate washout after the protocol ends. The [PCT planner](/pct-planner) estimates when to start post-cycle therapy.
Educational only. Not medical advice. Concentration values are modeled estimates based on population pharmacokinetics, not predictions of individual blood levels.